RAPID, REPRODUCIBLE, NON-INVASIVE PREDICTOR OF CADAVERIC DONOR LIVER GRAFT UTILIZATION

Abstract

A method for rapid, non-invasive assessment of liver function in a brain-dead donor, prior to procurement is presented. Quantitative assessment of liver function can be measured in brain-dead donors in the local donor service area prior to organ procurement by measuring indocyanine green plasma disappearance rates (ICG-PDR). This method can be performed with devices that use a non-invasive finger probe to obtain the ICG-PDR using pulse-densitometry.

Description

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not Applicable

INCORPORATION-BY-REFERENCE OF COMPUTER PROGRAM APPENDIX

Not Applicable

NOTICE OF MATERIAL SUBJECT TO COPYRIGHT PROTECTION

Not Applicable

BACKGROUND

1. Technical Field

The technology of this disclosure pertains generally to the assessment of liver tissue function, and more particularly to the rapid quantification of liver tissue function in brain dead donors to determine if liver tissue is acceptable for transplantation.

2. Background Discussion

Liver transplantation is the standard treatment for end-stage liver disease. Although the number of listed patients continues to grow, organ availability has plateaued resulting in increasing wait-list mortality. The donor pool has been somewhat expanded through the use of living donors, cadaveric split livers, and “extended criteria donors” (ECD). Used judiciously, the liver grafts from these sources provide an opportunity for addressing the organ shortage. However, these methods also predispose recipients to poor initial graft function and/or increased long-term risk. Factors that have been shown to affect graft utilization and function include advanced donor age, hypernatremia, prolonged warm ischemia time, pressor requirements, and donation after cardiac death.

Optimizing the use of these grafts while minimizing recipient risk requires accurate and reproducible assessments of graft quality. Clinical and laboratory criteria to measure liver quality are not reliable predictors. Therefore, the gold standard for assessing livers for transplantation remains the subjective decisions of surgeons. Attempts to evaluate all possible donors leads to inefficient use of resources, either by having surgeons evaluate many livers, only some of which are suitable for transplantation, or by having surgeons evaluate too few livers, thus forgoing useable grafts.

BRIEF SUMMARY

Using a portable, non-invasive device, indocyanine green plasma disappearance rates (ICG-PDR) can be measured in brain-dead donors in the local donor service area prior to organ procurement. This quantitative assessment of the donor's liver function can allow for an important initial assessment of a donor's liver prior to the surgeon's assessment for transplantation.

This quantitative assessment of liver function can save time and costs associated with the transportation of non-acceptable organs for transplantation. This initial evaluation may also save the surgeon time in trying to assess livers that are not functioning at optimal levels according to the ICG-PDR. Furthermore, because ICG-PDR is such a rapid test, unlike lengthy laboratory tests, it can be applied to measuring liver function repeatedly (˜20 measurements may be performed in a 24 hour period), if there is a suspicion that the liver has suffered damage before it is procured.

Non-invasive probes, such as finger probes, may be used to perform real time measurements without added risk to the donor's liver from invasive techniques. As an example, the LiMON by PULSION may be used.

In one embodiment, a threshold ICG-PDR value can be set at 18%, whereby livers with a measured ICG-PDR of at least 18% are procured for transplantation.

In another embodiment, a threshold ICG-PDR value can be set at 24%, whereby livers with a measured ICG-PDR of at least 24% are procured for transplantation.

Further aspects of the technology described herein will be brought out in the following portions of the specification, wherein the detailed description is for the purpose of fully disclosing preferred embodiments of the technology without placing limitations thereon.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

The technology described herein will be more fully understood by reference to the following drawings which are for illustrative purposes only:

FIG. 1 is a schematic diagram of how Indocyanine Green Plasma Disappearance Rates (ICG-PDR) may be measured, according to an embodiment of the described technology.

FIG. 2A is a close up view of a schematic diagram of ICG-PDR being measured using a non-invasive finger probe, according to an embodiment of the described technology.

FIG. 2B is a graph of fractional pulsatile changes in optical absorption at 805 nm.

FIG. 2C is a graph of fractional pulsatile changes in optical absorption at 905 nm.

FIG. 3 is an example graph of clearance of ICG (C_ICG) over time, used in the calculation of ICG-PDR.

FIG. 4A is a schematic diagram of a screen shot for a PULSION-LiMON ICG trace of an acceptable graft, according to an embodiment of the described technology.

FIG. 4B is a schematic diagram of a screen shot for a PULSION-LiMON ICG trace of a non-acceptable graft, according to an embodiment of the described technology.

FIG. 5 is a graph illustrating ICG-PDR in donors with acceptable and non-acceptable grafts.

FIG. 6 is a flow chart of the method of measuring the ICG-PDR in a brain-dead donor, according to an embodiment of the described technology.

DETAILED DESCRIPTION

Referring more specifically to the drawings, for illustrative purposes, embodiments of the methods for assessing livers in brain-dead donors using indocyanine green plasma disappearance rates (ICG-PDR) to determine liver function before a liver is procured for graft transplantation are described herein and depicted generally in FIG. 1 through FIG. 6. It will be appreciated that the methods may vary as to the specific steps and sequence without departing from the basic concepts as disclosed herein. The method steps are merely exemplary of the order that these steps may occur. The steps may occur in any order that is desired, such that it still performs the goals of the claimed technology.

Using portable, finger-probe based devices or other similarly non-invasive devices, ICG-PDR can be measured in adult brain-dead donors in the local donor service area prior to organ procurement. The method described herein provides a quantitative technique for assessing liver function in association with liver graft utilization.

Example

To evaluate the method for rapid, non-invasive, quantitative assessment of liver function, performed before liver graft procurement, a LiMON liver function monitor, manufactured by Pulsion Medical Systems, Munich, Germany, was used for the assessment of brain-dead donor livers by measuring Indocyanine Green Plasma Disappearance Rates (ICG-PDRs). Referring to FIG. 1, a schematic diagram 100 of how the ICG-PDR was measured in this example is presented. The LiMON monitor 102 measures Indocyanine Green (ICG) 104 clearance from the blood, after the ICG is administered intravenously to the donor, by non-invasive pulse-densitometry using, for example, a finger probe 106.

Referring to FIG. 2A through FIG. 2C, a close-up view 200 of ICG-PDR measurement by a non-invasive pulse-densitometry finger probe is presented. Injected ICG 202 is detected by a sensor 204 on the finger 206 from fractional pulsatile changes 208, 210 in optical absorption using LED lights 212. The optical peak absorption of 805 nm as shown in FIG. 2B and 905 nm as shown in FIG. 2C allows continuous measurements of ICG-PDR. The clearance of the injected dye from the blood (mg/l) can be calculated as:

$C_{\mathrm{ICG}}=\frac{{\mathrm{pulsatile}}_{905nm}/\mathrm{non}{\mathrm{pulsatile}}_{905nm}}{{\mathrm{pulsatile}}_{805nm}/\mathrm{non}{\mathrm{pulsatile}}_{805nm}}$

The ICG-PDR is calculated as the ICG clearance (C_ICG) over time, as shown in the graph in FIG. 3.

Consecutive adult brain-dead donors in the local donation service area, whose livers were offered to the study center, were assessed for liver function using the methods of the current disclosure, after permission was acquired. Immediately prior to organ procurement, indocyanine green elimination tests were conducted using the non-invasive liver function monitoring system shown in FIG. 1 and FIG. 2A. Each patient received an ICG finger clip connected to a liver function monitor. A dose of 0.25 mg/kg ICG (ICG—PULSION, Pulsion Medical Systems) was given through a central vein as a bolus and immediately flushed with 10 mL of normal saline. All of the ICG-PDR measurements were acquired using the LiMON liver function monitor manufactured by Pulsion Medical Systems, Munich, Germany. FIG. 4A shows a sample PULSION-LiMON ICG trace of an accepted liver 400 (PDR=21.5% clearance per minute). FIG. 4B shows a sample PULSION-LiMON ICG trace of a non-acceptable liver 402 (PDR=12.9% clearance per minute).

ICG-PDR measurements were performed on 53 consecutive brain-dead donors. Eleven liver grafts were declined due to quality and one was declined for size. Univariate analysis showed ICG-PDR to be the only factor associated with acceptance of an organ for transplantation. Donor Risk Index, donor age, and transaminase levels at peak or procurement were not significantly associated with utilization of liver grafts.

Additionally, there were no recipients who suffered from primary non-function and ICG-PDR was not associated with any post-operative outcome measures including POD7 AST (post-operative day 7 aspartate transaminase), ALT (alanine transaminase), Bilirubin, or INR (International Normalized Ratio—a measure of coagulopathy).

Results were correlated with surgeons' assessments and the decision to implant a graft. Both donor and recipient surgeons were blinded to ICG-PDR measurements. Post-transplantation labs of the recipient were recorded and correlated with the donor ICG-PDR.

Table 1 shows univariate predictors of liver graft utilization based on the data shown in Table 2 through Table 16. The data collected for the recipients of the liver grafts is presented in Table 2 through Table 7. The data collected for the donors of the liver grafts is presented in Table 8 through Table 16.

Table 2 shows the data for ICG-PDR, r15 (residual % of ICG at 15 minutes), Accept (graft accepted for transplant by primary center), TxAge (age of recipient at time of transplant), Gender, Expired 8/23/13 (recipient expired by 8/23/13), Dx1 (primary diagnosis) and Dx2 (secondary diagnosis) for the 53 recipients of the 53 donor liver grafts assessed. Table 3 shows the data for Race, Phys MELD (physiologic model for end stage liver disease score), INR (international normalized ratio—a measure of coagulopathy), Cr (creatinine), Tbili (total bilirubin), Plts (platelet count), Alb (albumin), and PAlb (prealbumin) for the 53 recipients of the 53 donor liver grafts assessed. Table 4 shows the data for Pressors, HD (hemodialysis), Vent (ventilator dependence), Redo (recipient is a redo liver transplant candidate), #OLT (number of liver transplant—i.e. first, second, third, etc.), L/K (combined liver/kidney transplant), HT (height), WT (weight), and BMI (body mass index) for the 53 recipients of the 53 donor liver grafts. Table 5 shows the data for Takeback# (number of times recipient was taken back to OR after transplantation), ReOLT (recipient was retransplanted after this graft), 7 d surv (7 day survival), 30 d surv (30 day survival), 6 m surv (6 month survival), 1 yr surv (1 year survival), Rpfn Bx (description of the reperfusion biopsy, and LD 1 d (lactate dehydrogenase on postoperative day 1) for the 53 recipients of the 53 donor liver grafts assessed. Table 6 shows the data for AST 1 d (aspartate transaminase on postoperative day 1), ALT 1 d (alanine transaminase on postoperative day 1), Tbili 1 d (total bilirubin on postoperative day 1), INR 1 d (INR on postoperative day 1), LD 7 d (day 7), AST 7 d (day 7), ALT 7 d (day 7), and Tbili 7 d (day 7) for the 53 recipients of the 53 donor liver grafts assessed. Table 7 shows the data for INR 7 d (day 7), LD 30 d (day 30), AST 30 d (day 30), ALT 30 d (day 30), Tbili 30 d (day 30), and INR 30 d (day 30), Age, and Male for the 53 recipients of the 53 donor liver grafts assessed.

For the 53 donor livers assessed, Table 8 shows the data for the donors' Age, Male, Race, ABO (blood type), Wt (weight), and Ht (height). Table 9 shows the data for BMI, Cause of Death, LOH (length of hospitalization), and Dopa (Dopamine) for each of the 53 donors assessed. Table 10 shows the data for Vaso (vasopressin), NE (norepinephrine), Phenyl (phenylephrine), Total Pressors, Insulin, DM (diabetes mellitus) and HTN (hypertension) for each of the 53 donors assessed. Table 11 shows the data for EtOH Abuse, Other Drugs, HgbA1c (Hemoglobin A1c level), HepB Core and HepC for the 53 donors assessed. Table 12 shows the data for whether the donor suffered Cardiac Arrest, Respiratory Arrest, the Total Downtime, CPR Duration and MAP range (mean arterial pressure range). Table 13 shows the data for MAP at Procurement of the liver grafts, Na Peak (sodium at peak), Na Proc (sodium at procurement), Cr Peak, Cr Proc, (creatinine at procurement) and TBili Peak (peak total bilirubin). Table 14 shows the data for TBili Proc (total bilirubin at procurement), AST Peak, AST Proc, ALT Peak and ALT Proc for each of the 53 donors assessed. Table 15 shows the data for INR Peak, INR Procurement, pH at Admission, pH at Procurement, pCO₂ at Admission and pCO₂ at Procurement for each of the 53 donors assessed. Finally, Table 16 shows the data for pO₂ at time of Admission, pO₂ at Procurement, HCO₃ at time of Admission, HCO₃ at time of Procurement, whether pO₂ was less than 60 and whether the donor's liver was Abnormal on Imaging.

FIG. 5 is a graph that illustrates ICG-PDR in donors with accepted and rejected liver grafts according to their ICG-PDR.

Referring to FIG. 6, a flow chart 600 that details a preferred embodiment of the disclosed method is presented. At box 610, ICG is administered to the brain-dead organ donor. Indocyanine green (ICG) is a water-soluble anionic compound. It can be administered intravenously and binds mainly albumin and β-lipoproteins in the plasma. ICG is selectively absorbed by hepatocytes, independent of adenosine triphosphate (ATP), and is later excreted unaltered into the bile via an ATP-dependent transport system. It is not metabolized and does not undergo enterohepatic recirculation. Thus, ICG is particularly useful for the assessment of liver function.

At box 620, the ICG-PDR is measured using a device such as the LiMON liver function monitor. The measurement is preferably performed non-invasively, such as with the finger probe sensor previously described. Once the ICG-PDR is measured, the result is compared to a threshold value 630. If the ICG-PDR falls below the threshold, the liver can be rejected for graft transplant. The surgeon can set a particular threshold and then procure and evaluate only those donors whose ICG-PDR meets the selected threshold 640.

The successful use of a portable, quantitative means of assessing liver function in association with graft utilization is described. The data collected thus far warrant further exploration in a variety of settings to evaluate acceptable values for donated organs. At a time of increasing regional and national organ sharing, the methods described herein can assist in increasing liver graft utilization while decreasing travel risk and expense.

From the description herein, it will be appreciated that that the present disclosure encompasses multiple embodiments which include, but are not limited to, the following:

1. A method for determining whether liver tissue will be acceptable for transplantation, the method comprising: (a) measuring indocyanine green plasma disappearance rates (ICG-PDR) in a brain-dead donor prior to organ procurement; and (b) designating liver tissue in the donor as acceptable for transplantation if the ICG-PDR is greater than about 18%.

2. The method of any preceding embodiment, further comprising designating the liver tissue as acceptable for transplantation if the ICG-PCR is greater than about 24%.

3. The method of any preceding embodiment, wherein ICG-PDR is measured non-invasively.

4. The method of any preceding embodiment, wherein ICG-PDR is measured using a PULSON LiMON liver function monitor.

5. A method of determining whether liver tissue will be acceptable for transplantation, the method comprising: (a) measuring indocyanine green plasma disappearance rates (ICG-PDR) in a brain-dead donor prior to organ procurement; (b) comparing measured ICG-PDR to a threshold; and (c) designating liver tissue in the donor as acceptable for transplantation if the ICG-PDR exceeds the threshold.

6. The method of any preceding embodiment, wherein the threshold is about 18%.

7. The method of any preceding embodiment, wherein the threshold is about 24%.

8. The method of any preceding embodiment, wherein ICG-PDR is measured non-invasively.

9. The method of any preceding embodiment, wherein ICG-PDR is measured using a PULSON LiMON liver function monitor.

Although the description herein contains many details, these should not be construed as limiting the scope of the disclosure but as merely providing illustrations of some of the presently preferred embodiments. Therefore, it will be appreciated that the scope of the disclosure fully encompasses other embodiments which may become obvious to those skilled in the art.

In the claims, reference to an element in the singular is not intended to mean “one and only one” unless explicitly so stated, but rather “one or more.” All structural, chemical, and functional equivalents to the elements of the disclosed embodiments that are known to those of ordinary skill in the art are expressly incorporated herein by reference and are intended to be encompassed by the present claims. Furthermore, no element, component, or method step in the present disclosure is intended to be dedicated to the public regardless of whether the element, component, or method step is explicitly recited in the claims. No claim element herein is to be construed as a “means plus function” element unless the element is expressly recited using the phrase “means for”. No claim element herein is to be construed as a “step plus function” element unless the element is expressly recited using the phrase “step for”.

TABLE 1
Univariate Predictors of Liver Graft Utilization
	Mean (SD)
	Rejected	Accepted	P
IGG-PDR (%/min)	17.9 (4.7)	24.1 (6.7)	0.006
Donor pH at Admission	7.40 (0.12)	7.31 (0.41)	0.06
Donor Length of	18 (36)	6.4 (5.8)	0.06
Hospitalization (days)
Donor Vasopressors (#)	2 (0.77)	1.6 (0.69)	0.10
Procurement ALT (U/L)	65 (39)	48 (47)	0.28
Peak ALT(U/L)	98 (73)	114 (186)	0.77
Donor Age (years)	47.9 (15.3)	43.8 (16.3)	0.48
Donor Risk Index	1.53 (0.39)	1.56 (0.40)	0.82

TABLE 2
	ICG-					Expired
Recipient	PDR	r15	Accept	TxAge	Gender	Aug. 23, 2013	Dx1	Dx2
1	no	no	0	25	F	1	Chronic
	read	read					Rjxn
2	23.1	3.1	0	25	F	1	Chronic
							Rjxn
3	no	no	0	27	M	0	9930	9940
	read	read
4	18.3	6.4	0	56	M	0	HepC	HCC
5	12.6	15.2	0	68	M	0	4202	HCC
6	16.9	7.9	0	24	F	0	4212
7	14.1	12.1	0	68	F	0	NASH	HCC
8	16.3	8.7	0	49	M	1	EtOH
9	27.7	1.6	0	45	M	0	HepB
10	22.2	3.6	0	46	M	0	HepC	HCC
11	size	size	0	74	F	0	EtOH
12	16.5	8.4	0	51	M	1	HepC	HCC
13	12.4	15.6	0	62	M	0	HepC	HCC
14	17.3	7.5	0	66	M	0	4213
15	no	no	0	60	M	0	Chronic
	read	read					Rjxn
16	28.7	1.4	1	52	M	0	HepC	HCC
17	28.7	1.4	1	65	M	0	EtOH	HCC
18	26.8	1.8	1	42	F	0	4100
19	no	no	1	59	F	0	HepC	NASH
	read	read
20	28.4	1.4	1	66	F	0	HepC	HCC
21	10.3	21.3	1	26	M	0	4100
22	19.5	5.4	1	64	M	0	NASH	HCC
23	27.5	1.6	1	60	F	1	NASH
24	25.3	2.2	1	44	M	0	HepC
25	36.2	0.4	1	56	M	0	4403	4245
26	28.3	1.4	1	61	M	1	9911
27	21.2	4.2	1	46	M	0	EtOH
28	18.3	6.4	1	52	M	0	4241
29	28.6	1.4	1	51	F	1	HepC	HCC
30	32.9	0.7	1	42	M	0	4241
31	23.9	2.8	1	52	M	0	4260
32	5.4	44.5	1	63	M	0	HepC	HCC
33	19.3	5.5	1	49	M	0	EtOH
34	27.7	1.6	1	44	M	0	HepC
35	19.9	5.1	1	63	M	0	HepC	HCC
36	20.2	4.8	1	50	M	0	HepC
37	24.9	2.4	1	60	M	1	HepC
38	25.8	2.1	1	45	M	1	4430
39	24.8	2.4	1	71	M	0	4216	HCC
40	16.2	8.8	1	52	M	0	EtOH
41	27.1	1.7	1	22	M	0	4100
42	33.8	0.6	1	57	F	0	EtOH
43	21.5	4	1	64	M	0	EtOH	HCC
44	14.8	10.9	1	62	F	0	4220	HCC
45	22.2	3.6	1	63	M	0	HepB
46	22	3.7	1	62	M	0	NASH	HCC
47	19.6	5.3	1	53	F	1	EtOH
48	23.9	2.8	1	68	F	0	4102	HCC
49	36.6	0.4	1	62	M	0	HepC	HCC
50	29.7	1.2	1	56	M	0	HepC	HCC
51	29	1.3	1	59	M	0	4213
52	15.6	9.6	1	65	M	0	HepC	HCC
53	27.6	1.6	1	65	M	0	Acute
							Rjxn

TABLE 3
		Phys
Recipient	Race	MELD	INR	Cr	TBili	Plts	Alb	PAlb
1	White	39	1.5	4	44.1	41	3	6
2	White	39	1.6	4	41.2	47	3.7	4
3	Hispanic	33	1.5	4	9	62	3.2	11
4	White	16	1.5	1	3.8	30	2.2	na
5	Asian	8	1.1	1	1.2	141	4	19.2
6	Hispanic	33	3.7	1	24	86	3.2	21.2
7	Hispanic	7	1.1	1	1	131	3.3	na
8	Hispanic	46	3.2	4	32.6	26	4	16
9	Asian	33	3.6	1	28.4	50	2.6	17.5
10	Hispanic	9	1.3	1	1	92	3.1	20.7
11	Black	39	3.2	2.2	25.1	76	3.2	4.2
12	White	19	1.7	1	6.1	59	2.3	3.3
13	White	7	1.1	1	1	82	3.4	25.3
14	Other	42	2.4	4	26.8	68	2.9	na
15	White	43	2.3	4	40.5	27	4	7.2
16	White	14	1.4	1	2.5	107	1.8	na
17	White	11	1.2	1	1.8	228	2.6	na
18	White	34	1.9	4	6.4	59	4	13
19	Hispanic	38	1.9	4	17.7	38	4.8	5
20	Hispanic	7	1.1	1	1	77	3.6	29
21	White	35	2.4	4	4	74	3.3	34
22	White	12	1.2	1	2.6	50	3.2	17
23	Hispanic	42	2.2	4	37.8	25	5.5	6
24	Black	30	2.3	1.5	14.2	36	3	13.2
25	Black	30	3.2	1	16.3	154	3.3	21.1
26	Hispanic	42	2.2	4	34	74	4.8	8.8
27	White	38	1.8	4	21.3	45	2.9	23.4
28	White	13	1.2	1	3.3	64	2.8	9.7
29	White	34	2	4	6.2	85	4.1	14.2
30	White	30	1.7	1.5	33.5	65	2.6	24
31	Hispanic	33	1.3	4	14.3	102	2.6	16.8
32	Hispanic	8	1.1	1	1.1	69	3.3	13
33	Hispanic	24	2.1	1	11	59	2.2	20.2
34	Hispanic	32	1.8	3	9.9	35	2.5	16.2
35	White	15	1.3	1.1	3.3	50	3	21.4
36	Hispanic	39	3.1	4	6.1	39	5	3.4
37	Other	42	2.2	4	38.3	57	3.1	5.1
38	Hispanic	9	1.1	1.2	1	224	4.6	26.7
39	Hispanic	8	1.1	1	1.1	57	3.7	19
40	Hispanic	16	1.4	1.5	1.6	74	3.5	26.3
41	White	42	3.3	4	11	61	3	10.5
42	White	32	2.4	1.7	15.8	74	2.4	17.1
43	White	10	1.3	1	1.3	64	3.3	na
44	Hispanic	9	1.1	1.1	1.2	62	3.2	12.5
45	Other	39	1.6	4	40.4	89	3.6	3.3
46	White	29	1.2	4	6.6	58	3.4	11.3
47	White	22	1.8	1.5	3.9	43	3.6	7.8
48	Asian	6	1	1	1	116	4.6	na
49	White	7	1.1	1	1	64	3.4	25.3
50	Hispanic	13	1.3	1	2.9	47	3.5	na
51	White	11	1.3	1	1.6	47	3.4	20
52	Black	8	1.2	1	1	144	3.9	12.1
53	Other	43	2.1	4	55.2	102	3.2	24.2

TABLE 4
Recipient	Pressors	HD	Vent	Redo	#OLT	L/K	HT	WT	BMI
1	0	1	0	1	4	1	152.4	53.1	22.86
2	0	1	0	1	4	1	152.4	53.1	22.86
3	0	1	0	1	3	0	167.64	62	22.06
4	0	0	0	0	1	0	188	96	27.16
5	0	0	0	0	1	0	162.56	65	24.60
6	0	0	0	0	1	0	162.56	100	37.84
7	0	0	0	0	1	0	152.4	70.91	30.53
8	2	1	1	0	1	0
9	0	0	0	0	1	0	170.18	97.27	33.59
10	0	0	0	0	1	0	160.02	75	29.29
11	0	0	0	0	1	0	165.1	56.7	20.80
12	0	0	0	0	1	0
13	0	0	0	0	1	0	180.34	90.73	27.90
14	0	0	0	0	1	0	170.18	60	20.72
15	0	1	0	1	2	1	190.5	76	20.94
16	0	0	0	0	1	0	175.26	76.36	24.86
17	0	0	0	0	1	0	203.2	109.09	26.42
18	0	1	1	0	1	0	154.94	76.32	31.79
19	1	1	1	0	1	0	167.64	110.45	39.30
20	0	0	0	0	1	0	160.02	94.09	36.75
21	1	1	1	0	1	0	177.8	85	26.89
22	0	0	0	0	1	0	172.72	98.18	32.91
23	3	1	1	0	1	0	160.782	67.64	26.16
24	0	0	0	0	1	0	185.42	79.55	23.14
25	0	0	0	0	1	0	180.34	75	23.06
26	1	1	1	1	2	0	167.64	83	29.53
27	1	1	1	0	1	0	177.8	68.4	21.64
28	0	0	0	0	1	0	177.8	84.09	26.60
29	0	1	0	0	1	0	152.4	56.7	24.41
30	0	0	0	0	1	0	180.34	79	24.29
31	1	1	1	1	2	1	165.1	68	24.95
32	0	0	0	0	1	0	182.88	95	28.40
33	0	0	0	0	1	0	177.8	110.45	34.94
34	0	0	0	0	1	0	170.18	117.27	40.49
35	0	0	0	0	1	0	187.96	74.27	21.02
36	0	1	0	0	1	0	167.6	79.4	28.27
37	0	1	0	0	1	0	167.6	71.2	25.34
38	0	0	0	0	1	0	175.26	112.27	36.55
39	0	0	0	0	1	0	162.56	69.45	26.28
40	0	0	0	0	1	0	165.1	80.45	29.52
41	0	1	1	0	1	0	172.72	68.4	22.92
42	0	0	0	0	1	0	167.64	72.91	25.94
43	0	0	0	0	1	0	162.56	83.64	31.65
44	0	0	0	0	1	0	154.94	78.27	32.60
45	0	1	1	0	1	0	162.56	72.27	27.35
46	0	1	0	0	1	1	182.88	110.45	33.03
47	0	0	0	0	1	0	162.6	66	24.96
48	0	0	0	0	1	0	157.48	71.81	28.96
49	0	0	0	0	1	0	180.34	90.72	27.90
50	0	0	0	0	1	0	165.1	64.64	23.71
51	0	0	0	0	1	0	170.18	81.82	28.25
52	0	0	0	0	1	0	180.34	88.64	27.25
53	0	1	0	1	2	1	172.7	65.6	21.99

TABLE 5
			7 d	30 d	6 m	1 yr	Rpfn	LD
Recip	Takeback#	ReOLT	surv	surv	surv	surv	Bx	1 d
1	na	na	na	na	na	na	na	na
2	na	na	na	na	na	na	na	na
3	na	na	na	na	na	na	na	na
4	na	na	na	na	na	na	na	na
5	na	na	na	na	na	na	na	na
6	na	na	na	na	na	na	na	na
7	na	na	na	na	na	na	na	na
8	na	na	na	na	na	na	na	na
9	na	na	na	na	na	na	na	na
10	na	na	na	na	na	na	na	na
11	na	na	na	na	na	na	na	na
12	na	na	na	na	na	na	na	na
13	na	na	na	na	na	na	na	na
14	na	na	na	na	na	na	na	na
15	na	na	na	na	na	na	na	na
16	0	0	1	1	1	1	Min IR,	969
							Min St
17	1	0	1	1	1	1	Mod IRI	2645
18	2	0	1	1	1	?	mild ir	2170
							mild st 20
19	0	0	1	1	1	?	Min IR,	169
							no st
20	0	0	1	1	1	1	Min IR,	550
							min st
21	0	0	1	1	1	1	0	1837
22	0	0	1	1	1	?	Min IR	337
23	3	0	1	1	0	0	mild ir	585
24	0	0	1	1	1	1	min IR	535
							mld St
25	0	0	1	1	1	1	mod IR	412
							min st
26	1	0	0	0	0	0	Sev nec,	5132
							no st,
							no fib
27	0	0	1	1	1	1	mild ir	904
							mild st 30
28	1 (wound)	0	1	1	1	1	Min IR	223
29	4	0	1	1	0	0	mild st	1395
							15-20
							md iri
30	0	0	1	1	1	1	No macro,	202
							80% micro
31	0	0	1	1	1	?	min ir	198
							no st
32	0	0	1	1	1	?	no st	378
							min IR
33	0	0	1	1	?	na	0	204
34	0	0	1	1	1	m	no st	298
35	0	0	1	1	?	na	mild st 10	1156
36	0	0	1	1	1	na	mild st	431
37	0	0	0	0	0	0	min st	na
38	4	1	1	0	0	0	min St	5060
							min IR
39	1	0	1	1	1	na	min St	319
							min IR
40	0	0	1	1	na	na	mild ir	359
							min st 10
41	2	0	1	1	1	na	Min IR,	1141
							min st
42	1	0	1	1	na	na	min ir	238
							min st
43	0	0	1	1	n	na	min IR	429
44	1	0	1	1	na	na	min IR	331
45	0	0	1	1	na	na	min ir	175
46	2	0	1	1	na	na	min IR	221
47	0	0	1	1	0	0	mild st	1158
							20 min
							ir fib
48	0	0	1	1	na	na	na	440
49	1	0	1	1	na	na	mild ir	2295
50	0	0	1	1	na	na	0	435
51	0	0	1	1	na	na	mild st	2560
							20 mod ir
52	0	0	1	1	na	na	no st	3984
							mod IR
53	1 wnd	0	1	1	na	na	mild ir	303

TABLE 6
	AST	ALT	Tbili	INR	LD	AST	ALT	Tbili
Recipient	1 d	1 d	1 d	1 d	7 d	7 d	7 d	7 d
1	na	na	na	na	na	na	na	na
2	na	na	na	na	na	na	na	na
3	na	na	na	na	na	na	na	na
4	na	na	na	na	na	na	na	na
5	na	na	na	na	na	na	na	na
6	na	na	na	na	na	na	na	na
7	na	na	na	na	na	na	na	na
8	na	na	na	na	na	na	na	na
9	na	na	na	na	na	na	na	na
10	na	na	na	na	na	na	na	na
11	na	na	na	na	na	na	na	na
12	na	na	na	na	na	na	na	na
13	na	na	na	na	na	na	na	na
14	na	na	na	na	na	na	na	na
15	na	na	na	na	na	na	na	na
16	742	374	4	1.1	266	37	127	1.8
17	2463	1018	4	1.5	250	46	311	2.8
18	1579	1957	3.9	1.1	279	45	186	5.7
19	100	119	3.7	1.1	154	14	38	1.8
20	273	327	2.6	1.2	468	117	411	1.2
21	4087	2688	1.5	1.1	323	43	341	1.7
22	669	561	3.4	1.2	190	36	157	1.5
23	791	463	14.7	1.3	354	45	126	28.8
24	530	360	2.3	1.2	413	49	108	2.8
25	681	672	5.7	1.3	575	53	204	3.6
26	6536	1985	5.3	1.5	na	na	na	na
27	1191	505	7.1	1.6	239	23	63	4.3
28	176	193	3.2	1.2	173	17	49	1.9
29	1642	1126	1.4	2.2	314	37	106	2.3
30	268	406	10.3	1.4	188	21	77	9.1
31	176	143	4.4	1.3	361	30	40	4.2
32	854	477	4	1.4	236	38	102	4.3
33	138	86	5.6	1.2	194	26	63	3.1
34	307	186	6.9	1.2	400	270	433	5.7
35	2374	1451	5.6	1.5	631	1605	1136	3.8
36	431	259	5.1	1.3	204	27	57	2.8
37	na	na	na	na	na	na	na	na
38	3385	2010	3.1	1.3	259	20	133	1.2
39	181	189	1.8	1.2	229	15	37	0.6
40	485	356	3.8	1.3	201	33	113	1.1
41	851	1546	10.5	1.4	399	59	379	3.1
42	344	527	3.4	1.2	190	20	59	5.8
43	839	846	0.9	1.3	251	25	104	0.6
44	268	256	22	1.1	549	114	136	2.7
45	89	179	6.4	1.2	363	15	31	3.5
46	347	141	5.1	1.5	157	11	20	1.4
47	992	296	4.3	1.5	240	39	62	4.7
48	293	406	0.6	1	349	38	111	0.6
49	1730	1112	2	1.5	306	59	204	2.5
50	466	523	2.3	1.3	382	55	147	1.4
51	3948	1645	3.4	1.3	286	43	266	1.7
52	3792	1505	3.1	1.5	191	67	202	1.5
53	197	103	20.8	1.1	257	26	75	16.3

	TABLE 7
		INR	LD	AST	ALT	Tbili	INR
	Recip	7 d	30 d	30 d	30 d	30 d	30 d
	1	na	na	na	na	na	na
	2	na	na	na	na	na	na
	3	na	na	na	na	na	na
	4	na	na	na	na	na	na
	5	na	na	na	na	na	na
	6	na	na	na	na	na	na
	7	na	na	na	na	na	na
	8	na	na	na	na	na	na
	9	na	na	na	na	na	na
	10	na	na	na	na	na	na
	11	na	na	na	na	na	na
	12	na	na	na	na	na	na
	13	na	na	na	na	na	na
	14	na	na	na	na	na	na
	15	na	na	na	na	na	na
	16	1.1	na	42	79	0.6	1.1
	17	1.1	231	36	85	0.9	1
	18	1.1	309	15	15	1.2	2.6
	19	1	195	9	8	1.1	1.1
	20	1.2	255	57	163	0.8	1.1
	21	1.5	313	22	28	0.8	1.1
	22	1.2	142	12	20	0.5	1.1
	23	1.2	388	101	236	7.4	1.1
	24	1.1	248	13	17	0.7	1
	25	1.1	177	21	21	1.6	1.1
	26	na	na	na	na	na	na
	27	1.1	136	14	7	0.9	1.2
	28	1.3	na	12	12	0.8	1.2
	29	1.3	298	113	90	18.4	1.2
	30	1.3	120	17	43	2	1.1
	31	1.1	266	16	14	1.5	1.1
	32	1.2	165	34	26	1.2	1
	33	1.1	na	16	13	1.8	na
	34	1.2	186	144	354	1.4	1.5
	35	1.3	na	23	25	1.2	na
	36	1.2	218	12	8	0.9	1.1
	37	na	na	na	na	na	na
	38	1.3	na	na	na	na	na
	39	1.2	160	9	7	0.5	1.1
	40	1.2	na	8	10	0.7	na
	41	1.1	215	24	40	1.1	1.2
	42	1.1	221	12	11	0.9	1
	43	1.2	na	13	16	0.4	na
	44	1.1	468	28	19	0.9	1
	45	1.1	178	15	5	1.8	1
	46	1.3	na	12	10	0.8	1.1
	47	1.2	128	16	9	1	1.2
	48	1.1	305	42	76	0.5	1
	49	1.2	253	129	328	0.6	1
	50	1.2	na	26	35	0.9	na
	51	1.2	195	17	38	0.6	1.1
	52	1.1	na	32	43	0.5	na
	53	1.3	202	9	8	1.3	1.1

TABLE 8
					Wt	Ht
Donors	Age	Male	Race	ABO	(kg)	(cm)
1	24	1	Latino	A	55	167.64
2	29	0	Latino	A	73	165.1
3	39	1	White	O	80	172.72
4	49	1	White	O	80	177.8
5	68	1	Asian	O	41	162.56
6	53	0	Latino	O	80	160.02
7	55	0	Latino	O	60	167.64
8	0	1	Asian	O	70	180.34
9	25	0	Black	A	80	162.56
10	65	1	White	B	73.5	170.18
11	57	0	White	A	49.2	160.02
12	30	1	White	O	120	188
13	59	1	White	A	102.5	180.34
14	46	1	White	O	80	170.18
15	50	0	White	O	65	167
16	22	1	White	O	85	180.34
17	54	1	White	A	115	187.96
18	43	1	Latino	A	77	172.72
19	20	1	Black	O	91.8	190.5
20	47	1	Latino	O	69.3	160.02
21	51	0	Latino	O	84	165.1
22	55	1	White	A	114	180.34
23	62	1	Asian	A	72	162.56
24	57	1	Latino	O	81.8	172.72
25	65	1	White	O	102	180.34
26	26	1	Asian	A	80	177
27	52	0	Latino	O	66	154.94
28	20	0	Black	B	81.8	182.88
29	45	0	Latino	A	86	170.18
30	22	1	White	B	73	177.8
31	41	1	White	A	70	180.34
32	67	1	Latino	A	80	170.18
33	32	0	Latino	B	65	165.1
34	22	1	Latino	A	71	170.18
35	69	0	Black	O	137	175.26
36	48	1	Latino	O	50	172.72
37	43	1	Latino	A	73	162.56
38	44	1	White	A	80	183
39	59	0	Latino	A	81	160.02
40	65	1	White	AB	85	185.42
41	49	1	Latino	A	84	167
42	17	1	Latino	B	83.6	182.88
43	23	1	Latino	O	79.4	170.18
44	61	1	Latino	O	66	157.48
45	51	1	Black	O	118	165.1
46	36	0	Latino	B	91.7	162.56
47	54	1	Latino	O	59.6	162
48	22	1	Asian	B	78	168
49	23	1	Latino	A	95	175
50	64	1	White	AB	69.1	162.56
51	25	1	White	A	77	170.18
52	60	1	Latino	O	87	161
53	26	1	White	A	64.6	175.26

	TABLE 9
			Cause of		Liver
	Donor	BMI	Death	LOH	Trauma	Dopa
	1	19.6	ICH	4	0	1
	2	26.8	ICH	6	0	1
	3	26.8	Anoxia	4	0	1
	4	25.3	ICH	4	0	1
	5	15.5	ICH	3	0	1
	6	31.2	ICH	125	0	0
	7	21.3	ICH	3	0	0
	8	21.5	ICH	4	0	0
	9	30.3	ICH	17	0	0
	10	25.4	ICH	7	0	0
	11	19.2	ICH	3	0	0
	12	34.0	Blunt Head	20	1	0
			Trauma
	13	31.5	Blunt Head	4	1	1
			Trauma
	14	27.6	Blunt Head	5	1	0
			Trauma
	15	23.3	ICH	5	0	0
	16	26.1	Penetrating	4	0	1
			head injury
	17	32.6	ICH	33	0	1
	18	25.8	Penetrating	5	0	0
			head injury
	19	25.3	Blunt Head	8	1	1
			Trauma
	20	27.1	Penetrating	6	0	1
			head injury
	21	30.8	ICH	4	0	1
	22	35.1	Anoxia	6	0	1
	23	27.2	ICH	3	0	0
	24	27.4	ICH	4	0	1
	25	31.4	ICH	2	0	0
	26	25.5	Penetrating	4	0	0
			head injury
	27	27.5	ICH	6	0	0
	28	24.5	Blunt Head	2	1	0
			Trauma
	29	29.7	ICH	4	0	0
	30	23.1	Blunt Head	4	1	0
			Trauma
	31	21.5	Blunt Head	4	1	0
			Trauma
	32	27.6	ICH	4	0	0
	33	23.8	ICH	5	0	0
	34	24.5	Anoxia	7	0	0
	35	44.6	ICH	4	0	0
	36	16.8	ICH	4	0	0
	37	27.6	Anoxia	14	0	0
	38	23.9	ICH	8	0	0
	39	31.6	ICH	3	0	0
	40	24.7	ICH	6	0	1
	41	30.1	ICH	22	0	0
	42	25.0	Penetrating	8	0	0
			head injury
			(GSW
			homicide)
	43	27.4	Blunt Head	10	1	0
			Trauma
	44	26.6	ICH	3	0	0
	45	43.3	ICH	6	0	1
	46	34.7	Anoxia	7	0	0
	47	22.7	Blunt Head	8	1	0
			Trauma
	48	27.6	Blunt Head	5	1	0
			Trauma
	49	31.0	Penetrating	3	0	0
			head injury
	50	26.1	Anoxia	8	0	0
			(suicide)
	51	26.6	GSW	3	0	0
			(homicide)
	52	33.6	ICH	5	0	1
	53	21.0	Blunt Head	3	1	0
			Trauma

TABLE 10
				Total
Donor	Vaso	NE	Phenyl	Pressors	Insulin	DM	HTN
1	1	0	0	2	1	0	0
2	1	0	0	2	1	0	0
3	1	0	0	2	1	0	0
4	1	0	0	2	0	0	0
5	1	1	1	4	1	0	1
6	1	0	1	2	1	0	0
7	0	1	0	1	1	1	1
8	1	1	0	2	1	0	0
9	1	1	0	2	1	0	0
10	1	1	0	2	0	0	0
11	1	1	0	2	0	0	0
12	1	0	0	1	1	0	0
13	1	0	0	2	1	0	1
14	1	1	0	2	1	0	0
15	1	1	0	2	1	0	1
16	0	0	0	1	1	0	0
17	0	0	1	2	0	0	1
18	0	0	0	0	1	0	0
19	1	0	0	2	1	0	0
20	1	0	0	2	1	0	0
21	0	0	0	1	1	0	0
22	1	0	0	2	0	0	0
23	1	1	0	2	0	0	0
24	1	0	0	2	1	0	1
25	1	1	0	2	0	0	0
26	1	1	0	2	1	0	0
27	0	0	0	0	1	1	1
28	1	0	0	1	1	0	0
29	1	1	0	2	1	0	0
30	1	1	1	3	0	0	0
31	0	1	0	1	0	0	0
32	1	1	0	2	0	0	1
33	1	1	0	2	1	0	0
34	1	0	0	1	1	0	0
35	1	1	0	2	1	0	1
36	1	0	1	2	0	0	0
37	1	0	0	1	1	0	0
38	1	1	0	2	0	0	1
39	1	1	0	2	0	0	1
40	1	0	0	2	1	0	1
41	1	1	0	2	1	0	0
42	1	0	1	2	0	0	0
43	1	0	0	1	0	0	0
44	1	0	0	1	1	1	1
45	1	1	0	3	0	0	1
46	1	1	0	2	0	0	0
47	0	1	0	1	1	0	0
48	1	0	0	1	1	0	0
49	1	1	0	2	1	0	0
50	0	1	0	1	1	1	1
51	1	0	0	1	1	0	1
52	0	1	0	2	1	1	1
53	0	0	1	1	0	0	0

TABLE 11
	EtOH			HepB
Donor	Abuse	Other Drugs	HgbA1c	Core	HepC
1	0	none	5.8	0	0
2	0	none	5.1	0	0
3	0	opiates	5.8	0	0
4	unk	IVDA, meth,	5.8	0	1
		heroine,
		marijuana
5	1	none	not done	0	0
6	0	none	6.0	0	0
7	0	none	8.9	0	0
8	0	none	5.3	0	0
9	0	meth,	5.5	1	0
		marijuana
10	0	none	not done	0	0
11	1	marijuana	not done	0	0
12	0	marijuana	5.6	0	0
13	0	marijuana	not done	0	0
14	1	mar, benzos	4.8	0	0
15	0	amphetamine	5.5	0	0
16	0	marijuana	5.2	0	0
17	0	none	5.1	0	0
18	0	none	5.5	0	0
19	0	amphetamine,	5.5	0	0
		THC
20	1	cocaine, meth	6.3	0	0
21	0	none	9.6	0	0
22	0	crack	6.8	0	0
23	0	none	not done	0	0
24	1	opiates,	not done	0	1
		marijuana
25	0	none	not done	0	0
26	0	none	5.3	0	0
27	0	none	13.9	0	0
28	0	none	5.5	0	0
29	0	none	6.3	0	0
30	0	none	5.1	0	0
31	0	IVDA, meth,	5.7	0	0
		prescript Rx
32	unk	none	not done	0	0
33	0	cocaine,	5.2	0	0
		opiates
34	0	cocaine,	not	0	0
		marijuana	done
35	0	none	not	0	0
			done
36	1	none	6.0	0	0
37	0	none	6.1	0	0
38	1	none	5.0	0	0
39	0	none	not	0	0
			done
40	0	none	6.0	0	0
41	0	none	6.4	0	0
42	0	none	5.4	0	0
43	0	marijuana	5.6	0	0
44	0	none	not	0	0
			done
45	0	none	5.7	0	0
46	0	none	5.1	0	0
47	1	none	5.8	0	0
48	0	marijuana,	5.3	0	0
		ecstasy,
		amphetamine
49	0	amphetamines	not	0	0
			done
50	0	none	not	0	0
			done
51	0	marijuana,	5.8	0	0
		ecstasy,
		amphetamine
52	0	none	not	0	0
			done
53	0	meth, benzo,	4.8	0	0
		marijuana

TABLE 12
	Cardiac	Respir	Total	CPR
Donor	Arrest	Arrest	Downtime	Duration	MAP range
1	1	1	8	8	64.3-136
2	0	0	0	0	69.7-107.7
3	1	1	32	32	69.3-119.7
4	0	0	0	0	72.3-123
5	1	0	unk	0	57.7-96
6	0	1	21	21	66.3-125
7	0	0	0	0	85.3-110.7
8	0	0	0	0	73.3-148.3
9	0	0	0	0	63.7-135.7
10	0	0	0	0	77.3-140.7
11	0	0	0	0	55.3-109
12	0	0	0	0	69-105
13	0	0	0	0	68-126.3
14	0	0	0	0	69.7-167.7
15	0	0	0	0	87.3-141
16	0	0	0	0	49.3-115.7
17	0	0	0	0	73-149
18	0	0	0	0	74.3-139.3
19	0	0	0	0	68-129.7
20	0	0	0	0	60-118.3
21	0	0	0	0	62-92.7
22	1	1	unk	unk	69.3-143
23	0	0	0	0	66.7-86
24	1	1	13	13	71-195
25	0	0	0	0	60.3-133
26	0	0	0	0	89-123.7
27	0	0	0	0	50.7-133
28	0	0	0	0	66.7-108.7
29	0	0	0	0	57.3-116
30	0	0	0	0	60.3-129.3
31	1	1	15	15	76.7-104.3
32	0	0	0	0	85.3-126.3
33	0	0	0	0	60.3-104
34	1	1	9	9	68.3-123.7
35	0	0	0	0	74-127.3
36	0	0	0	0	69.7-116.7
37	1	1	11	11	71.3-119.3
38	0	0	0	0	81.7-131.7
39	0	0	0	0	57.7-124.7
40	0	0	0	0	60-104
41	1	1	8	8	44.7-93.7
42	0	0	0	0	61-129.7
43	0	0	0	0	66.7-137.7
44	0	0	0	0	89.3-139.3
45	0	0	0	0	69.3-130
46	1	1	15	15	59.7-88.3
47	0	0	0	0	70-128.3
48	0	0	0	0	74.7-134.3
49	0	0	0	0	77.3-107.7
50	1	1	38	34	70-109.7
51	0	0	0	0	67-112.3
52	0	0	0	0	66-104
53	0	0	0	0	66-130

TABLE 13
	MAP @	Na	Na	Cr	Cr	TBili
Donor	procurement	Peak	Proc	Peak	Proc	Peak
1	78.7	167	146	0.7	0.5	1.3
2	113.3	173	146	3.9	3.7	1.7
3	106.3	157	151	1.08	0.74	1.2
4	84	162	155	1.1	0.9	1.0
5	71	165	131	1.4	2.9	1.7
6	104	151	149	0.9	0.9	1.5
7	80.7	140	134	8.3	6.4	1.1
8	93	160	149	2.7	2.5	4.9
9	115.7	191	154	2.7	2.7	1.6
10	114.3	169	150	1.6	1.4	1.7
11	55.3	154	151	0.8	0.7	0.7
12	86.3	152	144	6.7	3.9	0.9
13	102.3	155	149	1.79	1.0	1.8
14	91	160	130	1.1	0.5	2.9
15	94	188	147	2.71	1.61	1.3
16	111.7	152	151	1.1	0.9	2.2
17	106.7	152	150	1.3	0.6	1.1
18	105.7	148	148	3.5	2.7	3.2
19	122	158	145	1.1	0.8	0.4
20	101.7	160	157	2.17	1.09	2.6
21	78.7	147	154	6.67	5.59	0.7
22	96	175	151	2.4	1.5	1.8
23	71.7	137	136	0.85	0.52	1.1
24	88	159	150	1.1	1.1	0.7
25	65.3	179	164	2.0	2.0	2.4
26	81.7	151	136	2.6	0.6	0.7
27	97.3	159	149	2.2	2.0	0.6
28	75	148	148	2.4	1.3	0.8
29	95.7	169	145	1.4	0.8	0.9
30	71	164	157	1.49	1.07	1.8
31	91.7	167	157	1.3	1.1	0.5
32	105.7	156	153	2.7	2.7	3.6
33	83.7	167	136	1.0	1.0	1.2
34	100.7	150	146	2.4	2.1	1.0
35	70.7	166	140	1.1	1.0	0.7
36	112	161	144	0.8	0.5	1.8
37	101	150	141	5.2	5.2	1.5
38	93	149	139	0.7	0.76	2.1
39	91.7	171	146	0.99	0.99	0.8
40	85	173	138	2.48	2.16	0.6
41	85.3	156	136	4.2	3.6	0.9
42	84	174	154	1.2	0.7	4.4
43	90	169	138	1.4	0.9	0.8
44	90	151	145	1.4	1.4	0.9
45	116.3	165	141	2.8	2.0	1.3
46	72	153	153	1.38	1.38	0.5
47	102.7	168	139	0.7	0.6	0.6
48	84	159	145	1.7	1.0	1.5
49	111.7	160	153	1.6	1.4	0.8
50	99	149	142	4.4	4.1	1.3
51	76.3	146	144	9.0	8.4	2.4
52	81.7	172	157	3.9	3.9	2.4
53	130.7	156	151	2.14	1.94	3.0

	TABLE 14
		TBili	AST	AST	ALT	ALT
	Donor	Proc	Peak	Proc	Peak	Proc
	1	1.0	77	32	59	42
	2	1.1	45	28	21	21
	3	1.0	1185	268	1293	106
	4	0.9	109	49	194	87
	5	1.7	54	482	29	103
	6	0.6	55	20	61	33
	7	0.6	31	31	15	11
	8	3.7	111	54	49	40
	9	1.6	74	74	126	50
	10	1.7	216	41	209	107
	11	0.3	28	21	40	40
	12	0.4	370	130	197	131
	13	1.3	273	170	78	76
	14	1.6	128	34	100	53
	15	0.9	43	35	38	40
	16	1.2	59	29	14	15
	17	0.6	44	18	33	59
	18	1.5	77	24	32	14
	19	1.1	244	19	165	36
	20	0.9	60	94	150	26
	21	0.4	31	23	24	15
	22	1.1	619	22	973	169
	23	1.6	137	42	72	59
	24	0.4	41	39	37	37
	25	0.8	49	49	38	38
	26	0.9	38	24	34	23
	27	0.5	40	44	24	24
	28	0.8	720	727	200	227
	29	0.5	70	23	30	30
	30	1.1	127	25	235	80
	31	0.4	87	26	74	21
	32	3.2	37	28	27	11
	33	1.1	36	35	37	37
	34	0.2	163	163	158	158
	35	0.6	33	12	15	11
	36	0.9	82	37	49	27
	37	0.7	1677	69	531	26
	38	0.9	35	24	30	21
	39	0.8	59	48	55	50
	40	0.4	82	27	47	38
	41	0.9	33	22	51	27
	42	4.0	52	17	22	13
	43	0.6	52	25	33	30
	44	0.6	48	22	28	16
	45	0.5	24	17	28	16
	46	0.4	243	13	113	32
	47	0.6	59	31	40	20
	48	1.4	491	267	138	81
	49	0.4	51	18	32	28
	50	1.1	468	63	488	81
	51	1.4	194	29	168	81
	52	2.4	88	88	73	49
	53	3.0	333	183	78	74

TABLE 15
	INR	INR	pH @	pH @	pCO2	pCO2
Donor	Peak	Proc	Adm	Proc	@ Adm	@ Proc
1	12.7	1.14	7.47	7.47	29	33
2	1.96	1.45	7.45	7.49	34.8	33.8
3	1.62	1.62	7.25	7.45	31	38
4	1.1	1.0	7.38	7.39	34.8	35.1
5	2.0	1.4	7.19	7.27	53	37.2
6	1.2	1.2	7.42	7.35	30	41
7	1.6	1.6	7.48	7.39	40	29
8	2.1	1.5	7.55	7.42	25	34
9	11.7	1.0	7.58	7.34	29.1	29.4
10	1.8	1.5	7.35	7.38	48	44.9
11	1.22	1.07	7.46	7.39	32.4	30
12	1.7	1.3	7.24	7.44	47.3	41.1
13	1.42	1.1	7.41	7.47	37	38
14	1.1	1.1	7.37	7.43	36	37
15	1.5	1.3	7.44	7.4	39	32
16	15	1.3	7.31	7.51	49	35
17	1.17	1.09	7.4	7.46	37.7	126
18	1.6	1.1	7.35	7.44	40.2	39.5
19	1.26	1.26	7.43	7.45	19.3	40.3
20	8.73	1.45	7.34	7.46	33	34
21	1.79	1.79	7.41	7.26	44	39
22	1.65	1.51	7.15	7.37	96.7	41.5
23	1.01	1.2	7.2	7.35	48.2	34
24	1.03	0.99	7.07	7.35	31	41
25	1.9	1.8	7.35	7.4	39	31
26	1.37	1.1	7.4	7.47	36.2	37.4
27	1.1	1.0	7.52	7.46	30.7	32
28	1.3	1.2	7.34	7.43	29.1	33.9
29	1.7	1.5	7.29	7.42	36.7	30
30	1.9	1.2	7.09	7.4	77	38
31	1.1	1.1	6.99	7.38	95.7	48
32	1.7	1.4	7.53	7.42	30.4	25.3
33	1.5	1.1	7.44	7.39	26	30
34	1.0	1.2	7.44	7.45	32	35
35	1.4	1.1	7.38	7.34	43	32
36	1.2	1.1	7.44	7.48	56	36
37	1.3	1.3	6.95	7.34	57	44
38	1.04	0.99	7.38	7.46	34	39
39	1.67	1.5	7.51	7.42	23.9	35.6
40	1.58	1.47	7.34	7.35	36.9	39
41	1.4	1.4	7.46	7.39	27.6	35.3
42	1.42	1.16	7.30	7.34	35.2	66
43	1.5	1.8	7.4	7.6	31.9	24
44	1.6	1.4	7.39	7.35	29	33
45	1.2	1.2	7.23	7.36	61	49
46	1.55	1.55	7.25	7.44	33	28
47	1.3	1.3	7.34	7.54	36.8	26.6
48	1.27	1.18	7.24	7.43	42	40.2
49	1.2	1.1	7.41	7.37	39	50
50	1.16	1.1	7.21	7.9	32.3	32.3
51	1.77	1.07	7.26	7.36	45	42.5
52	1.4	1.4	7.28	7.47	31	26
53	1.35	1.1	7.18	7.34	58	53

TABLE 16
						Liver
						Abnormal
	pO2	pO2	HCO3	HCO3		on
Donor	@ Adm	@ Proc	@ Adm	@ Proc	pO2 < 60	Imaging
1	151	525	22.8	25	0	0
2	228	194	23.5	25.3	0	na
3	603	542	13	26	0	1
4	195	175	20.8	21.2	0	0
5	362	90.5	19.4	16.5	0	1
6	140	135	19	22	0	0
7	269	99	30	17.6	0	na
8	68	141	21.9	22.1	0	1
9	49	92.5	26.7	21	1	0
10	178	334	27	26.8	0	0
11	478	107	32.4	18	0	0
12	199	64	19.5	28	0	na
13	101	240	23.5	27.7	0	0
14	448	121	20.1	24	0	1
15	389	588	26.5	19.8	0	0
16	485	430	21.6	28.1	0	0
17	163	126	22.8	31.4	0	na
18	421	496	21.5	26.3	0	na
19	297	345	12.8	27.7	0	0
20	321	174	18	25	0	0
21	120	204	28	17.5	0	0
22	83.7	98.9	32	24.2	0	na
23	124	95.2	18.7	18.5	0	na
24	168	120	22	22.6	0	0
25	370	461	21.5	19.2	0	0
26	116	161	22.2	26.6	0	0
27	97.9	501	24.4	22	0	0
28	195	147	15.4	22.2	0	0
29	167	398	17.8	21.4	0	0
30	47	119	23	23.5	1	1
31	437	98.3	23.4	28	0	1
32	110	156	25.5	16	0	na
33	443	124	17	17.8	0	na
34	172	89	21.3	24.2	0	na
35	107	147	24.9	16.9	0	0
36	84.9	136	38.8	26.8	0	na
37	205	158	12.5	24.3	0	0
38	418	183	20.1	27.7	0	na
39	309	170	18.3	22.4	0	na
40	78	151	19.9	21.2	0	na
41	371	143	19.4	20.7	0	0
42	48.7	95	17.2	35	1	0
43	249	553	19	23	0	0
44	183	110	17.7	18.2	0	na
45	174	130	25.5	27.7	0	0
46	540	166	15.9	21.9	0	0
47	135	132	19.3	23.6	0	na
48	78.8	120	17.6	26.3	0	0
49	105	141	24.9	29.1	0	na
50	309	121	12.7	24.9	0	na
51	35	191	20.4	23.5	1	0
52	548	119	14.1	18.1	0	0
53	355	118	20	28	0	na

Claims

1. A method for determining whether liver tissue will be acceptable for transplantation, the method comprising: (a) measuring indocyanine green plasma disappearance rates (ICG-PDR) in a brain-dead donor prior to organ procurement; and(b) designating liver tissue in the donor as acceptable for transplantation if the ICG-PDR is greater than about 18%.

2. The method of claim 1, further comprising designating the liver tissue as acceptable for transplantation if the ICG-PCR is greater than about 24%.

3. The method of claim 1, wherein ICG-PDR is measured non-invasively.

4. The method of claim 3, wherein ICG-PDR is measured using a PULSON LiMON liver function monitor.

5. A method of determining whether liver tissue will be acceptable for transplantation, the method comprising: (a) measuring indocyanine green plasma disappearance rates (ICG-PDR) in a brain-dead donor prior to organ procurement;(b) comparing measured ICG-PDR to a threshold; and(c) designating liver tissue in the donor as acceptable for transplantation if the ICG-PDR exceeds the threshold.

6. The method of claim 5, wherein the threshold is about 18%.

7. The method of claim 5, wherein the threshold is about 24%.

8. The method of claim 5, wherein ICG-PDR is measured non-invasively.

9. The method of claim 8, wherein ICG-PDR is measured using a PULSON LiMON liver function monitor.